JPRN-UMIN000003945
Completed
Phase 1
A phase 1 study of adoptive immunotherapy using autologous RNF43 peptide pulse dendritic cells and RNF43 peptide specifically activated lymphocytes in patients with advanced solid tumors - RNF43 peptide pulse DC with specifically activated lymphocytes therapy
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- advanced solid tumors which already have finished available standard therapies.
- Sponsor
- Kyushu University Hospital
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Patients with severe pre\-exiting diseases :autoimmune diseases, an active infectious diseases, cardiovascular disorders, respiratory disorders, renal dysfunction, immunodeficiency, and hematological disorders. 2\.Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner 3\.No active brain metastases. 4\.Patients who should receive systemic administration of steroid or immunosuppressive agents. 5\.Inappropriate for study entry judged by an attending physician.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 1
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
Unknown
Phase 1
Phase I/II study of adoptive immunotherapy using predetermined minor histocompatibility antigen-specific cytotoxic T cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantation.1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000161Aichi Cancer Center30
Completed
Not Applicable
Phase I/IIa Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With PSA biochemical failure after radical prostatectomy.JPRN-UMIN000006617Tokyo Women's Medical University10
Active, not recruiting
Phase 1
Clinical study with autologous CIK cells for patients with advanced and uresectable sarcomapatients with advanced and non-resectable sarcomaMedDRA version: 20.0Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-002257-11-ITAOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO35
Completed
Not Applicable
Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell CarcinomaCytokine refractory Renal cell carcinomaJPRN-UMIN000004482Tokyo Women's Medical University35